Perspective Therapeutics develops radiopharmaceutical treatments using targeted alpha therapy to treat various cancers, including neuroendocrine tumors, melanoma, and prostate cancer. The company's pipeline includes VMT-a-NET for somatostatin receptor-positive neuroendocrine tumors, VMT01 for melanoma, PSV359 targeting fibroblast activation protein, and Pluvicto for metastatic prostate cancer, with several candidates currently in Phase 1/2a clinical trials. The company also collaborates with Bristol Myers Squibb on a combination study involving one of its therapies with an immunotherapy agent.
1Y: 2.88 (-12.5%) · range 2.05–5.65
entry readiness 81 · STRONG SETUP · exit proximity 0
Value area 2.80–3.79 · 94% of 120d volume overhead · heavy supply
| Source | Score | Last seen |
|---|---|---|
| short-interest | 1.000 | Aug 31, 2026 |
| squeeze-risk | 0.910 | Aug 31, 2026 |
| earnings-surprise | 0.033 | Sep 8, 2026 |
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -12.46% | +2.80% | 15/20d |
| 40d | -12.46% | +2.80% | 15/40d |